Data di Pubblicazione:
2020
Citazione:
Genetic and In Vitro Inhibition of PCSK9 and Calcific Aortic Valve Stenosis / N. Perrot, V. Valerio, D. Moschetta, S.M. Boekholdt, C. Dina, H.Y. Chen, E. Abner, A. Martinsson, H.D. Manikpurage, S. Rigade, R. Capoulade, E. Mass, M.-. Clavel, T. Le Tourneau, D. Messika-Zeitoun, N.J. Wareham, J.C. Engert, G. Polvani, P. Pibarot, T. Esko, J.G. Smith, P. Mathieu, G. Thanassoulis, J.-. Schott, Y. Bosse, M. Camera, S. Theriault, P. Poggio, B.J. Arsenault. - In: JACC. BASIC TO TRANSLATIONAL SCIENCE. - ISSN 2452-302X. - 5:7(2020 Jul), pp. 649-661. [10.1016/j.jacbts.2020.05.004]
Abstract:
The authors investigated whether PCSK9 inhibition could represent a therapeutic strategy in calcific aortic valve stenosis (CAVS). A meta-analysis of 10 studies was performed to determine the impact of the PCSK9 R46L variant on CAVS, and the authors found that CAVS was less prevalent in carriers of this variant (odds ratio: 0.80 [95% confidence interval: 0.70 to 0.91]; p = 0.0011) compared with noncarriers. PCSK9 expression was higher in the aortic valves of patients CAVS compared with control patients. In human valve interstitials cells submitted to a pro-osteogenic medium, PCSK9 levels increased and a PCSK9 neutralizing antibody significantly reduced calcium accumulation.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
aortic valve interstitial cell; apolipoprotein B; calcific aortic valve stenosis; LDL cholesterol; lipoprotein(a); proprotein convertase subtilisin/kexin type 9
Elenco autori:
N. Perrot, V. Valerio, D. Moschetta, S.M. Boekholdt, C. Dina, H.Y. Chen, E. Abner, A. Martinsson, H.D. Manikpurage, S. Rigade, R. Capoulade, E. Mass, M.-. Clavel, T. Le Tourneau, D. Messika-Zeitoun, N.J. Wareham, J.C. Engert, G. Polvani, P. Pibarot, T. Esko, J.G. Smith, P. Mathieu, G. Thanassoulis, J.-. Schott, Y. Bosse, M. Camera, S. Theriault, P. Poggio, B.J. Arsenault
Link alla scheda completa: